NASDAQ: CASI | 中文 | Contact Us

Other Assets

For Greater China market:

Marqibo Zevalin

CASI’s assets include a small portfolio of FDA-approved and FDA-pending ANDAs for generic products.

FDA-approved generic products for China market:

Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets – 50mg, Cilostazol tablets – 100mg, Ondansetron HCL tablets, and Tizanidine tablets

About Us

CASI is a U.S. NASDAQ-listed biopharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, the U.S., and throughout the world. We have offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China, through which substantially all of our operations are conducted.

Learn More